Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae(Northwestern University), Francis J. Giles(National University of Ireland), Jaehyuk Choi(Northwestern University), Wade T. Iams(Vanderbilt University Medical Center), Ayush Arya(Alliance for Clinical Trials in Oncology), Marcelo Cruz(Centro Científico Tecnológico - Nordeste), Sunandana Chandra(Northwestern University)
Cited by 468
Related Papers
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:
|Cancer|2006|607
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Genomic landscape of cutaneous T cell lymphoma
|Nature Genetics|2015|418